The use of clinical risk factors enhances the perfomance of BMD in the prediction of hip and osteoporotic fractures in men and women.
Publication date
2007
Authors
Kanis, J.A.
Oden, A.
Johnell, O.
Johansson, H.
de Laet, C.
Brown, J.
Burckhardt, P.
Cooper, C.
Christiansen, C.
Cummings, S.
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Farmacie/Biofarmaceutische wetenschappen (FARM), Epidemiology, Farmacie(FARM), Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health, SDG 3 - Good Health and Well-being
Citation
Kanis, J A, Oden, A, Johnell, O, Johansson, H, de Laet, C, Brown, J, Burckhardt, P, Cooper, C, Christiansen, C, Cummings, S, Eisman, J A, Fujiwara, S, Gluer, C, Goltzman, D, Hans, D, Krieg, M A, La Croix, A, McCloskey, E, Mellstrom, D, Melton, L J, Pols, H A, Reeve, J, Sanders, K, Schott, A M, Silman, A, Torgerson, D, van Staa, T P, Watts, N B & Yoshimura, N 2007, 'The use of clinical risk factors enhances the perfomance of BMD in the prediction of hip and osteoporotic fractures in men and women.', Osteoporosis International, vol. 18, pp. 1033-1046.